Document is current

Article History

Received: 10 February 2026

Accepted: 1 June 2026

First Online: 12 June 2026

Declarations

:

: Patients were enrolled in an observational study. Observational study was approved by the local institutional ethics board in accordance with the Declaration of Helsinki and its later amendments (Medical Faculty of the University of Duisburg-Essen, 21-10243 BO) and written informed consent was requested. For validation, observational study was approved by the local institutional ethics board (EK769/2010). Each individual gave written informed consent prior to imaging. Findings were compared to the Essen cohort. Each individual gave written informed consent to participate prior to imaging.

: Written informed consent was obtained from the participants for publication of this study and accompanying images.

: C. P. Spielvogel declares speaker and consulting fees from Pfizer. All other authors declare that there is no potential conflict of interest regarding this work.C. Rischpler, K. Herrmann and M. Hacker are editors of this journal.S. Settelmeier: received speaker honoraria from Astra Zeneca outside of the submitted work.A. Carpinteiro: Personal fees outside the submitted work for consulting and/or lectures from Alexion, Alnylam, Amgen, GSK, Janssen, Pfizer, Sanofi and Takeda and travel and congress participation grants from Janssen.M. Papathanasiou has received speaker and consultancy fees from Cytokinetics, Pfizer, Bristol Myers Squibb, AstraZeneca, Alnylam, Bayer, Alexion, Prothena, Janssen, Zoll, and Novo Nordisk, has participated in clinical trials sponsored by AstraZeneca, Novo Nordisk, Alnylam, and Cytokinetics and received research grants from Alnylam.C. Rischpler: Personal fees outside the submitted work for speaker honoraria (Alnylam, Bayer, Curium, GE Healthcare, Novartis, Pfizer, Rotop, Siemens Healthineers) and for consultancy (Pfizer, Novartis).T. Rassaf: Personal fees outside the submitted work from Novartis, Bristol Myers Squibb, Bayer, Daiichi Sankyo and AstraZeneca and Pfizer. Research funding: German Research Foundation (DFG; RA 969/12 − 1). Co-Founder of Mycor GmbH, a company focusing on artificial intelligence-based electrocardiography algorithms or the detection of amyloidosis [ ]. Co-founder of Bimyo GmbH, a company that develops cardioprotective peptides.L. Michel: Personal fees outside the submitted work from Bayer, Bristol Myers Squibb, Alnylam, AstraZeneca, IFFM e. V. and from Bund der Niedergelassenen Kardiologen (BNK). Research funding: UME funding from the Faculty of Medicine, University of Duisburg-Essen and Bayer for an investigator/institution sponsored collaborative study outside the submitted work. S.O. received travel and congress participation grants from Janssen and Alexion.M. Hacker and C. P. Spielvogel are members of the editorial board of the Journal.